Mobile

A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 26-WEEK TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DIMEBON (LATREPIRDINE, PF-01913539) IN PATIENTS WITH MODERATE-TO-SEVERE ALZHE...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-012456-25

A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 26-WEEK TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DIMEBON (LATREPIRDINE, PF-01913539) IN PATIENTS WITH MODERATE-TO-SEVERE ALZHEIMER’S DISEASE

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The co-primary objectives of this study are: 1. To determine the effect of dimebon, as compared to placebo, on the primary measure of cognition, the Severe Impairment Battery (SIB) in patients with moderate to severe Alzheimer’s disease (AD) 2. To determine the effect of dimebon, as compared to placebo, on the primary measure of self-care and daily function, the Alzheimer’s Disease Cooperative Study -Activities of Daily Living (severe) (ADCS-ADLsev) scale in patients with moderate-to-severe AD

Critère d'inclusion

  • Alzheimer's disease

Liens